2020 Revenues ($USD) : $8,945,495,411
2020 Revenues (foreign currencies) : JP¥955,200,000,000
2020 R&D spend : $1,927,327,215
2020 Number of Employees : not available
Fiscal Year End : 12/31/2020
Key People : Tatsuo Higuchi, CEO; Yuko Makino, CFO

The Otsuka group's pharmaceutical business has a focus on treatments involving the central nervous system and oncology. The group is also engaged in a wide range of other fields, including cardiovascular, gastroenterology, ophthalmology, diagnostics, clinical nutrition and medical devices. The Otsuka Pharmaceutical Factory (OPF) has been in the IV business in Japan for over 70 years. –CN